Clinical trials
Waldenstrom Macroglobulinemia trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 3 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 9 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Fondazione Italiana Linfomi - ETS | 3 |
| Gilead Sciences | 3 |
| BeOne Medicines | 2 |
| Eli Lilly and Company | 2 |
| ADC Therapeutics S.A. | 1 |
| AbbVie | 1 |
| Acerta Pharma BV | 1 |
| BeiGene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Waldenstrom Macroglobulinemia | 37 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 25 |
| Lymphoma, Follicular | 24 |
| Lymphoma, B-Cell, Marginal Zone | 23 |
| Lymphoma, Mantle-Cell | 23 |
| Lymphoma, Non-Hodgkin | 22 |
| Lymphoma, Large B-Cell, Diffuse | 19 |
| Burkitt Lymphoma | 14 |
| Multiple Myeloma | 14 |
| Hodgkin Disease | 12 |
Trials
Showing 26 to 37 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.